Healthcare (SH:603313)2021-04-29 16:00Financial Performance - Operating revenue rose by 78.52% to CNY 1,889,004,260.53 year-on-year[9] - Net profit attributable to shareholders decreased by 31.16% to CNY 55,268,176.42 compared to the same period last year[9] - Basic earnings per share decreased by 37.5% to CNY 0.15[9] - The company reported a significant decrease in net profit excluding non-recurring gains and losses, down 77.78% to CNY 18,768,995.20[9] - The company reported a net profit for Q1 2021 of CNY 65,540,471.37, a decrease of 26.9% from CNY 89,614,051.96 in Q1 2020[41] - The net profit attributable to shareholders of the parent company was CNY 55,268,176.42, a decrease of 31.1% from CNY 80,280,832.94 in Q1 2020[41] Cash Flow - Net cash flow from operating activities dropped by 240.85% to -CNY 115,699,362.09[9] - The net cash flow from operating activities decreased by 240.85% to -CNY 115,699,362.09, mainly due to rising raw material prices and increased procurement costs[18] - The company's operating cash flow for Q1 2021 was negative at approximately -¥115.70 million, compared to a positive cash flow of ¥82.14 million in Q1 2020[46] - The net cash flow from operating activities for Q1 2021 was -112,704,935.14 RMB, a significant decline compared to 5,556,367.86 RMB in Q1 2020, indicating a negative shift in operational cash flow[50] - The total cash flow for Q1 2021 was -155,118,952.81 RMB, slightly improved from -164,466,276.50 RMB in Q1 2020, indicating a narrowing of cash flow losses[50] Assets and Liabilities - Total assets increased by 18.22% to CNY 8,364,840,325.65 compared to the end of the previous year[9] - Total liabilities increased to CNY 4,633,285,751.09 from CNY 3,382,596,960.38, representing a growth of approximately 37%[29] - Current liabilities rose to CNY 3,167,101,762.26, up from CNY 2,683,006,329.01, indicating an increase of about 18%[29] - Non-current liabilities surged to CNY 1,466,183,988.83, compared to CNY 699,590,631.37, reflecting a significant increase of approximately 110%[29] - The company’s total assets and shareholders' equity increased to CNY 5,733,189,492.67 and CNY 3,490,284,646.99 respectively, compared to CNY 5,527,188,179.28 and CNY 3,461,052,407.55 in the previous year[37] Expenses - Operating costs rose by 103.67% to CNY 1,342,969,658.16, primarily due to increased sales and reclassification of logistics expenses[18] - Research and development expenses grew by 64.82% to CNY 30,456,850.43, reflecting increased investment in R&D[18] - Financial expenses surged by 334.75% to CNY 47,796,643.92, influenced by acquisition-related fees and exchange rate fluctuations[18] - The company’s management expenses increased by 128.51% to CNY 150,117,916.87, attributed to the impact of acquisitions and increased company scale[18] Shareholder Information - The number of shareholders at the end of the reporting period was 20,784[12] - The largest shareholder, Ni Zhanggen, holds 49.16% of the shares[12] Other Financial Metrics - The weighted average return on equity fell by 1.85 percentage points to 1.54%[9] - Non-operating income included government subsidies amounting to CNY 1,052,714.70[9] - The company reported an investment income of CNY 5,344,707.91 in Q1 2021, compared to a loss of CNY 1,144,179.27 in Q1 2020[41] - The total comprehensive income for Q1 2021 was CNY 43,436,221.87, down from CNY 72,319,658.75 in Q1 2020[41]